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ABSTRACT 
 
Background 
Rational and appropriate use of blood and blood products is important in a resource 
limited setting.  Proper education is required in decision-making and management 
with regard to blood transfusion. Current knowledge status is required in order to 
identify target areas of teaching. 
 
Objective 
To assess the knowledge regarding blood and blood products among doctors of 
varying ranks at the University of the Witwatersrand affiliated academic hospitals. 
 
Research design and methods 
This is an observational, descriptive study using a self-administered questionnaire. 
The questionnaire was divided into sections covering areas of red blood cells, 
platelets, plasma products, consent, blood ordering and side effects with a total of 40 
questions, approximately equally distributed in each of the above sections. A section 
on the demographics of the participants as well as an opinion section of how to impart 
further information was also included comprising of 2 questions each.  
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Results 
A response rate of 33% was obtained from the distributed questionnaires. The average 
score obtained for the questionnaire was 61% amongst all the doctors. The consultants 
achieved the highest score of 64%. In comparison, the interns, who averaged 56%, 
achieved the lowest score. The medical officers and registrars both averaged 63%. 
The community service doctors averaged 58%. A similar gradient was seen across the 
different sections of the questionnaire. 
Participants scored the best in the section pertaining to ‘consent’ with a score of 87%. 
The next best score (64%) was achieved for the section regarding ‘side effects’. The 
section regarding ‘red blood cell usage’ and ‘blood product ordering’ was scored at 
60%. The section with regards to ‘platelets usage’ achieved a score of 44%. The 
lowest score was achieved in the section regarding ‘plasma product usage’, i.e. 30%. 
A statistically significant gap in knowledge was noted from intern up to medical 
officer level, after which the increase in knowledge up to consultant level was not 
found to be statistically significant.  
 
Conclusions 
The overall results obtained appear to be suboptimal and can be improved upon 
significantly. Formalized and on-going teaching around blood and blood product 
usage is required at the University of the Witwatersrand affiliated hospitals, at all 
levels, from interns through to consultants to ensure that this scarce, but invaluable 
resource is used judiciously and appropriately. 
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In addition, knowledge about ‘blood and blood product transfusion’ should be 
introduced into the medical curriculum and reinforced particularly in the clinical 
years. Postgraduates should receive on-going and more detailed education and 
training as they progress from interns to specialists in the different fields / branches of 
medicine.  
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Introduction 
The introduction of blood products into the field of Medicine is undoubtedly a 
landmark in scientific history.  After a long and gruelling path of trial and error, 
experimentation and discovery dating as far back as the 17th century, the science of 
blood transfusion has reached advancements and achievements that have saved 
millions of lives over the years and has now become commonplace in modern 
Medicine (1). 
 
Blood and blood products are prescribed for use in patients often without hesitation.  
However, like any other medical prescription, consideration has to be given to a host 
of factors surrounding its usage including adverse effects, cost, availability and 
administration complexities.  These are not always advertised and easily referenced in 
a package insert.  In order to make appropriate decisions weighing in applicable risks 
and benefits, knowledge of these finer details of blood and blood product 
administration should be (and is thought to be) known to the practitioners prescribing 
them. However, this project will investigate how accurate this belief is (in our local 
setting). 
 
In a third world setting, appropriate management of this precious resource is 
particularly vital.  South Africa has a host of challenges affecting blood supplies.  To 
further compound low levels of voluntary blood donation and thus short blood supply 
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reservoirs, is the high demand of blood products owing to high rates of trauma, 
maternal morbidity and the scourge of blood borne diseases, particularly HIV and 
hepatitis infections, and to lesser extent other infections (2).  These blood transmitted 
diseases have resulted in the adoption of donor screening and blood safety policies by 
the South African National Blood Service (SANBS), which limits the donor pool as 
well as the amount of blood deemed safe for transfusion after screening (2,3).  
Clinically significant cytopaenias are also more common in the HIV population, 
adding to the demand of blood products (4). These factors make it more important for 
practitioners to be cautious in the responsible and appropriate use of blood products. 
 
In a ‘rainbow society’ such as South Africa, practitioners must always be mindful of 
ethical issues and contraindications that might obstruct the use of blood products and 
suitable alternatives must be considered.  Supported by the National Health Act of 
2003, which states that every patient has the right to participate in any decision 
affecting his or her personal health and treatment, practitioners need to be mindful of 
patient autonomy and diverse religious and cultural beliefs including Jehovah’s 
Witnesses (5). 
 
It is taken for granted as to when, how, and how much blood and blood products need 
to be prescribed by the doctor.  Although there are no fixed criteria available to apply 
in decision making with regard to transfusions, there are always new guidelines being 
formulated to assist in this regard, as new information comes to the fore (6).  This 
project plans to investigate whether medical doctors are keeping up to date with 
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current practice or if they are still practicing that which they have learnt and may be 
out-dated. 
 
Transfusion medicine is gaining popularity as a sub-specialty throughout the world. 
The development of specialised transfusion medicine departments demonstrates the 
importance of having a basic understanding of blood products and it’s usage.  
Introduction of transfusion protocols is an important step in standardizing 
management of blood and blood products.  Many protocols and guidelines are in 
place for obstetric and surgical disciplines, but blood and blood product usage in 
internal medicine is rapidly growing and guidelines are being formulated, made 
available, and updated, especially in the developed world (6).  In South Africa, the 
University of Free State now offers a post-graduate diploma in transfusion medicine.  
Despite this, currently there is limited information regarding publications on the 
knowledge of blood and blood product use in the South African context (7). 
  
In conclusion, rational and appropriate use of blood and blood products is important 
in a resource limited setting.  Proper education is required in decision-making and 
management with regard to blood transfusion.  This project will investigate the 
adequacy in knowledge among medical doctors working at the University of the 
Witwatersrand affiliated teaching hospitals, in an attempt to identify if there is a need 
for undergraduate and postgraduate training in transfusion medicine. 
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1.2 Legal framework  
Blood services and administering facilities are currently regulated in terms of Section 
68 of the National Health Act 61 of 2003.  This Act encompasses issues related to the 
use of licensed blood services, the standards of functioning and the regulation thereof; 
as well as the appropriate requisition and administration of the products (8).  
 
1.3 Batho Pele Principles 
The principle of Batho Pele (‘People First’) is an initiative of the South African 
government from the Mandela administration to ensure quality of public health 
services (9).  These principles can be applied to all aspects of health care.  Health care 
workers should be aware of these principles as it pertains to the use of blood and 
blood product transfusion. 
• CONSULTATION: Patients should be consulted and their choices respected 
regarding transfusions. 
• SERVICE STANDARDS: Clinicians should follow recommended guidelines 
where applicable. 
• ACCESS: Blood and blood alternatives should be available for use. 
• COURTESY: Patients should be treated with courtesy and consideration for 
their beliefs.  
• INFORMATION: Patients should be given full and accurate information 
regarding transfusions. 
• OPENNESS AND TRANSPARENCY: Patients should be aware of the things 
that are happening with their management. 
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• REDRESS: Complaints should be attended to and remedied effectively 
especially if the level of service is not achieved.   
• VALUE FOR MONEY: Responsible usage of allocated resources to ensure 
that as many citizens as possible are treated. 
• ENCOURAGING INNOVATION AND REWARDING EXCELLENCE: 
Blood product alternatives should be considered and sought when necessary.  
 
1.4 Ethical considerations 
Attention of the reader is drawn to the information provided in the Health Professions 
Council of South Africa (HPCSA) booklet. Written and verbal consent should be 
taken for all medical procedures, including all types of blood or blood product 
transfusion, as per guidelines provided by the HPCSA and in accordance to Chapter 2, 
Section 7 of the National Health Act 2003 (8, 10).   
 
Informed consent implies that the patient be of sound mind and be appraised of all 
possible risks, benefits, methods, potential side-effects, and alternatives in a language 
the patient understands. Thus the doctor needs to be knowledgeable and keep up to 
date with all aspects of transfusion medicine to assist the patient through the process 
(10).   
 
Doctors should accept the patients’ decisions and be mindful of specific patients and 
their beliefs.  For example, it is acceptable to some Jehovah’s Witnesses to receive 
blood derivatives such as albumin, cryoprecipitate, coagulation factors and 
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immunoglobulin.  However, they do not accept primary blood products such as red 
cells, platelets, and plasma (11).  It is important to discuss the details with each 
patient in order to ascertain their personal beliefs and recognize and offer acceptable 
alternatives to blood transfusion (12). 
 
1.5 Blood and blood products 
Donated blood (whole blood) is packaged in a sterile technique into a sodium citrate 
containing container.  This acts as an anticoagulant and pH buffer.  Samples are 
centrifuged to separate red cell concentrates, the buffy coat layer (rich in leukocytes 
and platelets) and plasma (12).  Centrifugation physically separates the plasma from 
the rest of the blood components.  Blood products are usually separated both for 
different uses and for storage purposes as they have different lifespans ex-vivo (13). 
Additives such as adenine, glucose, saline and mannitol are added to red cell 
concentrates to increase the viability for extended storage (12).  
 
Plasma components such as fresh frozen plasma and cryoprecipitate are obtained 
through centrifugation (14).  Plasma derivatives such as albumin, immunoglobulin 
and factor VII and IX are obtained from multiple plasma donations (pooled plasma) 
through complex processing (12). 
 
Red cell concentrates can be further filtered to remove more leucocytes after removal 
of the buffy layer.  Leucodepletion helps to decrease the risk of febrile non-
haemolytic transfusion reactions, to decrease the risk of Cytomegalovirus (CMV) 
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transmission and should be used in chronic transfusion regimens, massive 
transfusions, transfusions in infants and transfusions in patients at risk for CMV 
infection (12). Whole blood is rarely used nowadays. Indications include massive 
transfusions where all components are required. 
 
1.6 Red blood cell Transfusion 
1.6.1 Background 
An understanding of the human circulation recorded as early as 1260 AD by an Arab 
scholar and physician Ibn Al Nafis, who, amongst various other medical subjects, 
documented vital descriptions of the pulmonary circulation (15).   It was not until 
over two centuries later that William Harvey published descriptions of the human 
circulation.  The earliest recorded attempts of transfusion were in the 1600’s with 
animal experimentation and were soon prohibited due to fatal reactions.  This 
gradually progressed to the first human-to-human transfusion in 1818 by James 
Blundell.  The breakthrough discovery of blood groups (ABO) in 1900 and 
subsequently the suggestion of cross matching in 1907 heralded the beginning of safer 
transfusion practices.  Rhesus (Rh) identification was another vital turn-point, 
occurring in 1939.  The first blood bank was instituted in the United States in 1940 
(16). 
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1.6.2 Aim 
The aim of transfusion of red blood cells is to improve oxygen delivery to tissues 
when the demand for oxygen is not met (12).  This can be due to acute blood loss or 
acute decompensation in a chronic anaemia. 
 
1.6.3 Physiology 
Impaired oxygen delivery due to hypovolemia or anaemia is initially tolerated through 
compensatory mechanisms, such as: 
i. increased cardiac output 
ii. increased oxygen offloading at the tissues due to increased red cell 2,3 
diphosphoglycerate and due to decreased pH at the hypoxic tissues 
iii. increases in plasma volume 
iv. redistribution of blood flow to vital organs (12). 
 
The use of crystalloids and colloids are usually the first choice in replacement fluids 
and are a vital alternative.  However, when this form of intravenous fluid replacement 
is inadequate, red blood cell transfusion is often necessary. One unit of packed red 
cells can increase the haemoglobin level by 1-2 g/dl (12). 
 
1.6.4 Indication 
There are no well-defined criteria to describe the ideal level of haemoglobin at which 
to transfuse, and the use of a ‘transfusion trigger’ (i.e. haemoglobin concentration 
below which there is an indication for a transfusion) is variable and cannot be used as 
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the sole indicator of the need for transfusion (6).  Most studies in particular involve 
pre- or post-operative or surgical cases.  Data with regard to medical cases are fewer.  
General considerations are whether the patients are pre- or post- operative cases, prior 
to certain procedures, the chronicity of the anaemia and risks of cardiac failure or 
overload (12). A 2011 Cochrane systematic review of prospective randomized trials 
compared high versus low haemoglobin concentration thresholds of 19 trials 
including 6264 patients (17).  The findings favoured a more restrictive approach i.e. 
the use of lower haemoglobin thresholds, in general less than 7 g/dl.  The approach 
was well tolerated and decreased the need for transfusion thereby decreasing the risks 
and costs associated with it.  There is little evidence of transfusing to haemoglobin 
levels above 10 g/dl.  Haemoglobin levels between 8-10 g/dl are associated with low 
risks of hypoxic damage; however, the clinical picture should also be considered (12).  
 
1.6.5 Apheresis and storage 
About 300-350 ml of red blood cells are obtained from a single donor (18).  The 
blood is stored in approved refrigerating units between 2 °C to 6 °C for up to 42 days 
(18).  The ‘storage lesion’ refers to the changes that occur in the red cells during 
refrigeration and these include reduced life span, changes in red cell shape (due to 
reduction in ATP), reduced rigidity (due to reduced lipid content in the cell 
membrane), increased lactate and potassium in the solution, decreased pH, and 
increased free iron and haemoglobin in the solution. 2, 3 diphosphoglycerate (2, 3 
DPG) is an organic phosphate that binds haemoglobin and facilitates oxygen delivery.  
Levels of 2, 3 DPG decline in storage, thereby increasing the oxygen affinity of 
haemoglobin, making it less likely to release the oxygen particles.  This suboptimal 
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oxygen delivery in ill patients is thought to be a mechanism behind multi organ 
dysfunction, but is clinically unproven (13).  
 
1.6.6 Administration 
ABO and Rh compatible units are screened for irregular antibodies, cross-matched 
and issued.  Informed consent should be obtained and careful monitoring should take 
place during and after the transfusion.  The unit should be checked prior to transfusion 
for leaks and verifying the patient’s details and the red cell details (including expiry 
date). Transfusion should be started within 30 minutes of removal from the 
refrigerator under aseptic technique through a blood administration set (12, 18).   
 
The rate of transfusion depends on the clinical condition of the patient, where rapid 
transfusion may be appropriate for acute blood loss and slow transfusion (about 
2ml/min) with the use of intravenous diuretics, may be applicable for patients likely 
to develop fluid overload (12).  A relatively slow rate of 5 ml/min for the first 30 
minutes is advised to check for reactions.  Transfusion should occur over 2-4 hours 
and be completed within 6 hours of commencement of the transfusion (18).   
 
Warming is indicated for massive or rapid transfusions, transfusions through central 
lines, hypothermia, patients with high titre cold haemagglutinins and for neonates 
undergoing exchange transfusion.  Special blood warmers should be used.  Blood 
should never be warmed above 37°C in order to prevent it haemolysing and causing 
renal failure. No medications or fluid should be given in the same line as the blood 
transfusion, in order to prevent reactions with the blood.  The only fluids safe to 
	 11	
administer are calcium free solutions such as normal saline, modified Ringers lactate, 
Balsol, 4% albumin, compatible plasma and plasma protein fractions (12). 
 
1.6.7 Red blood cell alternatives 
No product to date has been found to replace blood in carrying out its function. The 
following have been tried with varying results: 
• Intravenous or oral iron supplementation 
• Haemopure 
• Erythropoiesis stimulating agents with iron supplementation 
• Autologous blood donation 
• Blood salvage techniques 
 
1.6.8 Products available and costs 
The 2014 (19) and 2016 (20) pricelist is shown in Appendix A. 
 
1.7 Platelet Transfusion 
1.7.1 Background 
Duke made a compelling discovery in 1910 describing the haemostatic effect of 
whole blood donations in thrombocytopenia (21). Platelet transfusions were 
recognized in the treatment of acute leukaemia from the 1950s (16).  Advancements 
in medical knowledge and technology have led to better collection, preparation, 
storage, and infection control.  
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1.7.2 Aim 
The aim of a platelet transfusion is to stop or prevent bleeding in patients with low 
platelet counts (usually severe thrombocytopaenia) or dysfunctional platelets. 
 
1.7.3 Physiology 
Therapeutic platelet transfusions should occur at a dose that would enable adequate 
haemostasis in active bleeding and efficacy measured by the clinical picture.  
Prophylactic platelet transfusions occur conventionally at a platelet level of less than 
10x109/l.  The best measure of effectiveness is a 1 hour post transfusion platelet 
count, which should rise by at least 5 x 109 /l or rise above the threshold or 
‘transfusion trigger’ (12).   
Corrected count increment (CCI) can be calculated as: 
Platelet increment x109 x body surface area (m2) x1011 
Platelet dose x1011 
 
A CCI greater than 7,5 – 10 x 109/l from a sample drawn 10 minutes to 1 hour after, 
or a CCI greater than 4.5 x 109/l 18-24 hours post transfusion is considered acceptable 
(i.e. not indicative of refractoriness). Anything less than these values will be 
considered ineffective. 
 
Causes of refractoriness to transfusion can be divided into immune and non-immune 
causes.  Non-immune causes include fever, sepsis, disseminated intravascular 
coagulopathy, drugs (such as vancomycin, amphotericin, heparin), hypersplenism, 
and age of the product/viability, veno-occlusive disease and bleeding. 
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Immune mediated causes include antibodies to ABO groups (also expressed by 
platelets), platelet specific antibodies and HLA allo-immunisation (usually in patients 
requiring multiple platelet transfusions).  The risk of HLA allo-immunisation can be 
reduced by leucodepletion, UV-B irradiation of platelets, and by using single donor 
platelets, thereby limiting donor exposure.  When allo-immunisation does occur, HLA 
matched platelets may be necessary (22). 
 
1.7.4 Indication  
A transfusion trigger that is generally recommended is a platelet count of less than 10 
x 109 /l.  This is however, for stable patients and this threshold may be higher in 
certain cases such as fever, sepsis, or rate of drop of platelet count.  Procedures such 
as lumbar puncture, epidural anaesthesia, gastroscopy, or liver biopsy usually require 
counts above 50 - 70 x 109 /l.  CNS and ocular procedures require levels above 100 x 
109 /l (22). 
 
1.7.5 Apheresis and storage  
Platelets can either be collected from multiple whole blood donations or from single 
donor apheresis, which limits the donor exposure thereby decreasing the risk of HLA-
alloimmunisation (12).  This is useful in patients requiring chronic transfusions. 
An important aspect of platelet transfusion is the continuous agitation of units during 
storage and transport.  This is to prevent sedimentation, which would decrease the 
amount of oxygen accessible to platelets (22).  Oxygen is vital to platelet metabolism.  
Platelets are stored at temperatures between 20-24°C, as temperatures below this 
cause cell damage (18).  These temperatures however, increase the likelihood of 
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bacterial growth; therefore storage is limited to 3-5 days. The short storage period is 
also related to the short lifespan of platelets (12,18).   
 
1.7.6 Administration 
The platelet bag should be inspected and the contents should be a cloudy yellow/straw 
colour (12). It should be administered immediately after it is collected from the blood 
bank through a platelet administration set over a period of 15-30 minutes (17).  Lines 
previously used for red cell concentrate transfusions should ideally be avoided. No 
medications or fluid should be given in the same line to prevent reactions with the 
platelets (12).   
 
1.7.7 Platelet transfusion alternatives 
The following have been investigated in the use for patients with low platelets but no 
definitive data is yet available on its efficacy. 
• Microspheres 
• Infusible platelet membranes 
• Cryopreserved/lyophilized platelets 
 
1.7.8 Products available and costs 
The 2014 (19) and 2016 (20) pricelist is shown in Appendix A. 
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1.8 Plasma Transfusion 
1.8.1 Background 
The 1960’s heralded the recognition of coagulation factor concentrates in the 
treatment of Haemophilia. By the 1980’s, advances in medical knowledge and 
technology allowed the use of plasma components / products and exchange 
transfusion in the treatment of various coagulation and autoimmune disorders (16).   
 
Because viruses are still transmissible via plasma, plasma donations in South Africa 
are ‘donor retested’ donations, which means that only blood from donors who donate 
subsequent donations are used as plasma products. Plasma components are derived 
from the centrifugation process.  It is then rapidly frozen to -18°C to produce fresh 
frozen plasma with the normal constituents of blood in the body: coagulation factors, 
solutes.  Plasma may be treated with methylene blue or ultraviolet light to inactivate 
transmissible viruses (12).   
 
Cryoprecipitate is formed by thawing to 4°C and re-suspending in a small volume of 
plasma.  It contains half the amount of factor VIII and fibrinogen when compared to 
whole blood.  Six or more donors may be pooled for preparation of cryoprecipitate.  
The remainder is referred to as cryo-poor FFP or cryo-supernatant and is used for 
plasma exchange in Thombotic Thrombocytopaenic Purpura (TTP) (12,18).  
 
1.8.2 Aim 
Plasma products are used in cases of active bleeding to replace factor deficiencies, 
which may be single or multiple factor deficiencies. Plasma is also used to replace 
fibrinogen in cases of acquired coagulopathies such as Disseminated Intravascular 
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Coagulopathy (DIC) and in plasma exchange which may be a therapeutic modality in 
TTP and a myriad of autoimmune disorders. 
 
1.8.3 Physiology 
Fresh frozen plasma (FFP) is a hyperosmolar solution and care should be taken to 
prevent overload in at risk patients. The constituents of FFP include (12): 
 
Table 1.1 Constituents of Fresh Frozen Plasma 
Glucose 24.8 mmol/L 
Potassium 3.2 mmol/L 
Sodium 165 mmol/L 
Chloride 79 mmol/L 
Osmolarity 322 mmol/L 
pH 7.9 
Fibrinogen 500 mg/unit of FFP 
Factor II 1.03 IU/mL 
Factor V 0.64 IU/mL 
Factor VII 1.21 IU/mL 
Factor VIII 0.85 IU/mL 
Factor IX  0.95 IU/mL 
Factor X 1.25 IU/mL 
Factor XII 0.79 IU/mL 
Anti-thrombin III 104 IU/mL 
Plasma pseudo-cholinesterase 3000 - 10000 IU/mL 
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Cryopreciptate contains: 
• Factors VIII 
• von Willebrands Factor 
• Fibrinogen  
• Fibronectin  
• Factor XIII. 
 
1.8.4 Indications 
FFP: may be used to treat coagulation deficiencies such as in liver failure, massive 
transfusions or warfarin toxicity.  It may also be used in DIC and TTP with active 
bleeding and abnormal coagulation tests (12,18).  FFP may also be used in single 
factor deficiencies if specific factors are not available (12). 
Cryoprecipitate: may be used in patients with congenital or acquired 
hypofibrogenaemia (laboratory value less than 1g/l) or dysfibrinogenaemia (12,18).   
Cryopoor FFP: may be used in plasma exchange in TTP (12). 
Pathogen reduced plasma: should ideally be used for massive or repeated transfusions 
to decrease the risk of transmissible diseases (12,18). 
 
1.8.5 Apheresis and storage 
Plasma from single donors is collected and frozen within 6 hours. It is stored at -25°C 
or lower for up to 1 year (18).  
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1.8.6 Administration 
Plasma is usually clear to straw coloured (12).  It must be infused within 6 hours of 
thawing, at temperatures between 30°C to 37°C through a blood administration set, as 
rapidly as possible (18).   
The usual dose of FFP is 10-15ml/kg. However, in TTP a dose of 30-40ml/kg is used. 
The dose of cryoprecipitate is 1 unit/10kg body weight (18).  It is usually available in 
15 ml units. 
 
1.8.7 Plasma transfusion alternatives 
A variety of recombinant factors are now available, such as factor seven, eight, nine, 
etc., with many still in development. 
 
1.8.8 Products available and costs 
The 2014 (19) and 2016 (20) pricelist is shown in Appendix A. 
 
1.9 Important points regarding the ordering of blood and blood products 
Due to resource limitations and possible risks of transfusions, practitioners have the 
responsibility to order and administer blood appropriately.  This means that once it 
has been ascertained that the transfusion is necessary or could become necessary, after 
obtaining consent, the right blood should be ordered and administered to the right 
patient, at the right time, in the right setting.   
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1.9.1 Ordering 
When ordering blood or blood products, the practitioner should be mindful of how 
soon the product is needed and weigh the benefits and risks of issuing blood that is 
not cross-matched. Blood specimens, colloquially referred to as a ‘compat’, is sent to 
the blood bank for typing (determining ABO and Rh blood group), screening (for 
irregular antibodies) and cross matching (patient serum with donor red cells to check 
compatibility) for blood transfusion (12, 13).  
 
Emergency blood consists of Group O blood that is not screened or cross-matched 
and can be issued immediately within 5-10 minutes. Emergency cross-match consists 
of ABO and Rh typing and minimum irregular antibody screening requires 20 - 30 
minutes to issue. Standard cross-match consists of ABO and Rh typing, screening for 
irregular antibodies as well as cross-matching with donor blood and is done within 2 
hours. It can be kept for up to 24 hours. Type and screen blood is only screened for 
ABO, Rh and irregular antibodies and not yet cross-matched until it is requested. It 
can be kept for up to 72 hours (23).   
 
Platelets also express ABO antigens and transfusions should ideally be ABO 
compatible.  However, ABO incompatible platelets may be used if the patient is 
unlikely to receive repeated transfusions. Repeated transfusions result in an increase 
of anti-A and anti-B titres and a resultant decrease in post transfusion platelet count 
(12).   
 
Plasma should preferably also be ABO compatible.  If compatible blood is 
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unavailable, blood from a different blood type can be used if there are low titre 
antibodies (12).  Only Group O plasma should be used for blood type O patients. 
 
1.9.2 Administration 
Care should be taken to administer the blood to the right patient.  The patient should 
be identified verbally if possible as well as by the hospital identification tags.  The 
blood or product bag should be checked for leaks or suspected contamination, and the 
information label inspected to confirm that it is the right blood. The blood type should 
be compared with previous transfusions, and the expiry date should be checked.  It 
should be given at the correct temperature in the correct time frame and through an 
appropriate administration set. The patient should be monitored before, during and 
after transfusion by charting the temperature, pulse rate, respiratory rate and general 
condition (12, 13).  
 
1.10 Potential adverse effects of blood transfusion 
An adverse transfusion reaction can be defined as any undesirable event related to the 
transfusion of blood or blood products either as a direct result or as an interaction 
between the recipient and the product (12). Haemovigilance is a vital component in 
transfusion medicine and encompasses monitoring of the entire chain of events from 
donation to transfusion; as well as surveillance of adverse events and reactions related 
to transfusion of blood and blood products.  Ensuring ‘blood safety’ is key to the 
ethical concept of  ‘do no harm’ and haemovigilance is a legal requirement in terms of 
the National Health Act 61 of 2003 (8).  The South African Haemovigilance system is 
a relatively young system, which was initiated in 1999-2000.  As such, it has shown 
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increasing levels of reporting over the years as the amount of issues increase as well 
as education and collaboration between all involved parties improve (24).   
 
In 2014, at the time of the distribution of the questionnaire, about 1 million units of 
blood and blood products were issued in South Africa.  The reported rate of 
transfusion reactions was 83.5 per 100 000 issues.  Acute events were the most 
common (67.6%).  Below is a table reflecting the distribution of adverse events 
secondary to blood transfusions as per the SANBS, for the year 2013 (24). 
			
Table 1.2 Distribution of Adverse Events due to Blood Transfusions in South Africa 
for 2013 (24)  
Adverse event Rates per 100 000 units issued 
Acute Transfusion Reactions - total 78.2 
Acute Haemolytic Transfusion Reaction  0.9 
Allergic Reactions 19.8 
Severe Allergic Reactions 2.0 
Anaphylactic Reactions 4.6 
Febrile Non-haemolytic Transfusion Reactions  30.1 
Transfusion Associated Circulatory Overload  0.3 
Transfusion Related Acute Lung Injury  0.2 
Transfusion Associated Dyspnoea  6.9 
Hypotensive Reactions 4.9 
Unclassifiable (Incomplete information) 8.3 
Unclassifiable (No forms) 0.3 
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Delayed Transfusion Reactions – total  0 
Delayed Haemolytic Transfusion Reactions  0 
Delayed Serological Reactions  0 
Incorrect blood components transfused - total 3.0 
ABO Incompatible Transfusions 1.0 
Misdirected Transfusions 0.6 
Patient Misidentifications 0.9 
ABO + Rh Incompatible Transfusions  0.5 
Other reactions – total  2.3 
Near Miss 0.7 
Transfusion Associated Graft versus Host Disease  0.0 
Transfusion Transmitted Infections  0.2 
Post Transfusion Purpura 0.0 
Mortality 1.4 
TOTAL 83.5 
83.5 
Of note, the United Kingdom Serious Hazards of Transfusion (SHOT) 
Haemovigilance report for 2013 found that 77.8% of reactions occurred due to 
avoidable errors at any point of the transfusion chain, whereas SANBS recorded only 
3.6% due to incompatibilities or misidentifications (24).  This implies that better 
surveillance is required across the entire process of blood donation, processing and 
transfusion.   
 
On suspicion of a reaction, one should: 
• Stop the transfusion immediately. 
• Maintain IV access, but change the administration set. 
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• Investigate further by returning the unit/bags/administration set to the blood 
bank, filling out an adverse event form and sending blood and urine specimens 
to the blood bank. 
• Monitor and treat any resulting complications.  
• Any serious or life threatening event must be reported to the Director-General 
by the blood bank in terms of the National Health Act (12). 
 
Adverse reactions can be grouped into acute or delayed reactions, and immune or 
non-immune reactions, as shown in table 1.3. 
 
Table 1.3 Classification of adverse reactions to blood transfusions 
Reaction  Immune  Non-immune 
Acute (less than 24 hours) Acute haemolytic 
transfusion reactions 
Bacterial contamination 
Febrile non-haemolytic 
transfusion reactions 
Transfusion-associated 
circulatory overload 
Anaphylactic reactions Thrombophlebitis 
Allergic reactions Air embolism 
Transfusion-related acute 
lung injury 
 
Delayed (more than 24 
hours) 
Delayed Haemolytic 
Transfusion reaction 
Transfusion transmissible 
infections 
Post transfusion purpura Iron overload 
Transfusion associated 
graft versus host disease 
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1.10.1 Acute reactions 
These are reactions that occur up to 24 hours of receiving a blood or blood product 
transfusion (18). Fevers, chills, pruritus or urticaria are most commonly encountered 
and usually resolve without intervention (6). 
 
1.10.1.1 Acute intravascular haemolysis 
The transfused red blood cells are destroyed, either intravascularly or extravascularly. 
Accidental transfusion of incompatible products is the most common cause (ABO 
mismatch) (6).  There is a spectrum of clinical effects ranging from fever, back pain, 
anxiety, hypotension and chest pain as well as DIC and renal failure (6,12).  These 
systemic manifestations are thought to occur due to the complement activation by the 
IgM antibodies and thus causing red cell lysis. Laboratory evidence may show a fall 
in haemoglobin, raised lactate dehydrogenase (LDH) and a positive Coombs test (25). 
 
1.10.1.2 Febrile non-haemolytic transfusion reaction 
There is an increase in body temperature of  > 2oC, or an isolated fever > 38oC, with 
no features of allergy or haemolysis.  This may be caused by passively transfused 
cytokines or a reaction to the recipient’s antibodies or leukocytes from the donor’s 
blood. This is commonly found in multiparous or multi-transfused patients. They 
present very similar to a patient with acute haemolysis but have no laboratory 
evidence of haemolysis (6). 
 
	 25	
1.10.1.3 Anaphylaxis 
Anaphylaxis may be suspected when one of the following is associated with 
hypotension: urticaria, rash, dyspnoea, angioedema, stridor, wheeze or pruritus. This 
is associated with antibodies to IgA (6).  Adrenalin and steroids may be required 
(6,12). When muco-cutaneous symptoms occur without the above-mentioned 
symptoms, it is called an allergic reaction. This can be treated with antihistamines 
(12). 
 
1.10.1.4 Bacterial contamination 
Rapid onset of signs of sepsis, such as fever, hypotension, gastroenteritis, renal failure 
and shock, may suggest contaminated blood products, most commonly platelets, due 
to aforementioned high storage temperatures favouring bacterial growth (12). 
 
1.10.1.5 Transfusion associated lung injury (TRALI) 
Within four hours of initiating the transfusion, recipients develop fever, hypotension, 
tachypnoea and dyspnoea. A chest x-ray shows diffuse bilateral pulmonary infiltrates 
with a clinical impression of non-cardiogenic pulmonary oedema. Acute hypoxia is 
associated without left atrial hypertension (6). It is far more severe than pulmonary 
oedema. This is due to leukocyte agglutinins, which is present in donor blood (6, 12). 
A two-hit hypothesis is suggested for this to occur: first the neutrophils need to adhere 
to the pulmonary endothelium, and then activation of the neutrophils causes 
endothelial damage. The acute parenchymal damage caused is reversible. Supportive 
management is sufficient but ventilation might be required in severe cases. 
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Multiparous female donors increase the risk for the development of TRALI, but 
screening to exclude such at risk donors is difficult to implement practically (25). 
 
1.10.1.6 Transfusion associated circulatory overload (TACO) 
TACO occurs when the patient cannot cope with the rapid volume expansion due to 
underlying cardiac pathology or chronic anaemia. Four of the following features are 
required for the diagnosis of TACO: 
• Acute respiratory distress 
• Tachycardia 
• Increased blood pressure 
• Pulmonary oedema 
• Positive fluid balance 
Fluid overload needs to be managed appropriately. This can be prevented by slower 
infusion rates in suspected individuals as well as use of diuretics during transfusion 
(12). 
 
1.10.2 Delayed reactions 
These are reactions that occur after 24 hours of receiving a blood or blood product 
transfusion. 
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1.10.2.1 Delayed intravascular haemolysis 
Delayed intravascular haemolysis is caused by destruction of transfused red blood 
cells, due to exposure to atypical IgG antibodies (anti-Kell, anti-Duffy, etc.) from the 
donor (12).  It usually presents with a drop in haemoglobin after the transfusion, 
which can also have other clinical implications such as auto-immune haemolytic 
anaemia, renal failure and occult bleeding. It usually occurs in individuals that have 
been immunized to red cell antigens, making its occurrence more common in females 
and previously transfused males. This can occur up to 28 days after the transfusion. 
Treatment is of a supportive nature (25). 
 
1.10.2.2 Transfusion associated graft vs. host disease 
transfusion of blood from a related donor can lead to bone marrow hypoplasia 
developing within a month after receiving the transfusion. This is due to allogeneic 
lymphocytes from the donor that share an HLA haplotype with the recipient (12).  
Lymphocytes proliferate and destroy host cells (18). Irradiating the blood of close 
family member donors can prevent this condition, as leucodepletion is not considered 
adequate in preventing this reaction (12,18). Patients present with jaundice, 
maculopapular rash, bone marrow hypoplasia and diarrhoea and will require 
specialized oncological / haematological care. 
 
1.10.2.3 Post transfusion purpura 
Mucosal bleeding, haemorrhage and purpura on pressure areas that occur due to 
thrombocytopenia developing approximately 2 weeks after transfusion is known as 
post transfusion purpura. This is due to recipient alloantibodies against donor platelet 
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antigens directed against the Human Platelet Antigen system (12). It is more common 
in females. Immunosuppressive therapy in the form of intravenous gamma globulin 
and steroids is required in the treatment of this condition (25). 
 
1.10.2.4 Transfusion Transmissible Infections 
The blood bank screens all donations for HIV, Hepatitis B and C, and syphilis (12).  
Only 2 cases of transfusion-transmitted infections were reported in 2014.   
Any infection in which a microbe circulates in the blood stream and is able to survive 
in stored blood components can be transmitted by transfusion. Of note are the 
following infections (25): 
Viral: Cytomegalovirus, Ebstein-Barr virus, Parvovirus, Human T-cell lymphotropic 
virus 1 & 2. 
Bacterial: Yersinia Enterolitica, Staphylococcus epidermidis, Pseudomonas. 
Parasites: Malaria, Trypanosoma, Babesia, Borrelia. 
Prion: Creutzfeldt-Jacob disease. 
 
1.10.2.5 Massive transfusion  
A massive transfusion is defined as one of the following (26): 
• Infusion of five or more red blood cell concentrates within 4 hours 
• Infusion of six or more red blood cell concentrates within 12 hours 
• Infusion of 10 or more red blood cell concentrates within 24 hours 
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Due to the biochemical and functional characteristics of the red cell concentrate units 
the following potential complications can occur: 
Coagulopathy: The platelet count is inversely proportional to the number of units 
transfused. This is due to the dilutional effect of the transfused blood. In order to try 
and achieve haemostasis, the body also consumes platelets and coagulation factors 
(25). 
Hypothermia: The transfusion of large amounts of rapidly infused cold blood causes 
the energy requirements to be increased in an effort to raise the body temperature. 
This increases the oxygen affinity of the haemoglobin, impairing citrate and lactate 
metabolism and promoting potassium release from the intracellular space. Warming 
blood in this instance is thus imperative (25). 
Hyperkalaemia: This is usually secondary to large transfusions of whole blood or 
blood older than 5 days, due to the inactivity of sodium-potassium-ATPase pump at 
storage temperatures and resultant gradual increase in extracellular potassium (18).   
Hypocalcaemia: This is due to citrate toxicity in large transfusions. It occurs due to 
the citrate additive that acts as a chelator of calcium (18).   
Hyperglycaemia: This is due to the glucose additives in the blood bag (12,18). 
Acid-base balance: Due to the presence of lactic acid and citric acid in the stored 
blood, there is a high acid load, which may exaggerate an already present metabolic 
acidosis from the bleeding and shock. Alkalinizing agents give a high sodium load, 
which can further impair oxygen release and thus these agents need to be 
administered based on results rather than arbitrarily (25). 
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Assessment of learning needs is an integral part of furthering education, but each 
group of people have their own learning needs, with the outcome needing to reach the 
same end point (27). Identifying what the needs are is helpful in planning further 
education in a way that recipients find appropriate. 
 
A recent study was conducted at Chris Hani Baragwanath Academic Hospital in the 
surgical specialties including Obstetrics and Gynaecology, Anaesthetics, 
Orthopaedics and General Surgery.  It set out to assess the knowledge and 
competencies related to blood and blood products among this group of clinicians and 
found significant deficits in awareness of risks, consent, costs, ordering and 
administration protocols (28). This study aims to assess similar themes in the 
Medicine department (see section 2.2, page 31). 
 
Knowledge regarding transfusion medicine is deficient in both first and third world 
countries (29). Very few questionnaires have been validated although many have been 
formulated. The questions in this study have been extrapolated from a validated 
questionnaire to make it comparable to international studies (30). 
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CHAPTER 2: METHODS 
 
A carefully formulated questionnaire, identifying key areas of knowledge around 
usage of blood and blood products, was circulated among the doctors in the 
Department of Medicine at the three University of the Witwatersrand affiliated 
hospitals, i.e. Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani 
Baragwanath Academic Hospital and Helen Joseph Hospital. Doctors were then given 
an opportunity to complete the questionnaire, after agreeing to participate, and to 
return the completed questionnaire for review and collection. Participant’s responses 
were collated using Microsoft Excel spread sheets. This was then analysed and put 
into graphs and tables to facilitate interpretation of the answers. 
 
2.1 Study Design 
A prospective, descriptive, contextual study design was used. 
 
2.2 Aims and objectives of the study 
- To determine the knowledge that exists about blood and blood products, including 
indications for its use, the correct ordering patterns, cost, side effects, and safe 
administration using a self-administered questionnaire. Understanding and 
consideration of ethical issues surrounding administration of blood and blood 
products, and available alternatives were also included in the questionnaire. 
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- To assess gaps in knowledge of doctors with regard to factors mentioned above and 
to identify targets of potential education and improvement. 
 
2.3 Study Population 
The study population included doctors at all levels of qualifications, namely interns, 
community service doctors, medical officers, registrars and consultants, in the 
Department of Medicine at the University of the Witwatersrand affiliated hospitals, 
i.e. Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath 
Academic Hospital and Helen Joseph Hospital. 
 
A convenience sampling method was used. Questionnaires were distributed to the 
different categories of doctors mentioned above. The returned questionnaires were 
collected and collated. From a statistical point of view, approximately two hundred 
questionnaires were required, thus this was the aim. 
 
2.4 Questionnaire Development 
The literature was reviewed in order to develop a questionnaire that was relevant and 
comparable. Some of the studies in the literature used questionnaires while others did 
not. Questions could further be extrapolated from the results. This was used as a 
preliminary guide (30). Questions were formulated using the South African Blood 
Service Clinical Guidelines for the use of Blood Products in South Africa as well as 
previous surveys found in the literature search (11 - 26). 
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The questionnaire was divided into three sections (see Appendix B). 
The first section was in regard to demographics i.e. the professional rank of the 
participant as well as the hospital at which they worked. 
 
The second section was further divided into sub-sections, as this was the section 
related to the blood and blood products. A number of questions on different aspects of 
blood transfusion related to this section were included in the questionnaire. 
 
The questions with regard to the usage of red blood cells, platelets and plasma 
products also included pricing of the product. Indications for ordering the various 
products as well as the duration over which the different products need to be 
transfused were also asked in the study questionnaire.  
 
With regard to the section on consent, the questions centred around how to obtain 
consent; from whom should consent be obtained, as well as what to do should a 
person refuse consent for personal or religious reasons. 
 
The section that covered ordering patterns of blood and blood products was meant to 
show the close liaison between the doctor and the blood bank. The different methods 
of ordering blood and what they mean, what is required when ordering the different 
products as well as how to return blood is captured in this section. 
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Side effects of blood products should be considered whenever one decides to 
administer them. Recognition and appropriate management of these side effects are 
vital and life saving. This aspect was also included in the questionnaire. 
 
A panel of doctors, namely an anaesthetist, physician, emergency medicine physician 
and a haematologist, validated the questionnaire. Their different backgrounds would 
allow reliability and validity of the questionnaire both in content and reproducibility. 
The panel was also requested to grade the questions according to difficulty; easy, 
average and difficult; as well as importance; all doctors should know, should be 
known at registrar level or at specialist level. They assessed it individually and all had 
similar responses. Table 2.1 depicts the scoring system allocation for the 
questionnaire. 
 
 
Table 2.1 Grading of questions 
Question Difficulty Importance 
Red blood cells 
Cost Average All doctors 
Storage duration Easy All doctors 
When to use a blood warmer Average All doctors 
Transfusion duration Average All doctors 
Haemoglobin increase Easy All doctors 
Transfusion level Easy All doctors 
When to use leucodepleted blood Average Registrar level 
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Platelets  
Cost Average  Registrar level 
Storage duration Average  All doctors  
Storage temperature Average  All doctors  
Transfusion duration Easy All doctors  
Transfusion level Easy All doctors  
When to use apheresis platelets Average  Registrar level 
Plasma products 
Cost Average  Registrar level 
Shelf life Average  All doctors 
Transfusion duration Average  All doctors 
DIC dose Average  Registrar level 
TTP dose Average  Registrar level 
When to use cryo-poor FFP Difficult Specialist level 
When to use cryoprecipitate  Difficult  Specialist level 
Consent  
Products requiring consent Easy All doctors 
Type of consent Easy All doctors 
Who can give consent Easy All doctors 
Who should take consent Easy All doctors 
What information to give for consent Easy All doctors 
What to do if consent unavailable Average Registrar level 
Non-blood alternatives Difficult Registrar level 
Ordering of blood 
When compat needed Average  All doctors 
How long a compat should be kept for Average  All doctors 
How long to wait for other blood 
products 
Average  All doctors 
What is understood by type, screen Average  All doctors 
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and hold 
How long is blood kept once ordered Average  All doctors 
Transfusion sets Average  All doctors 
Blood returns Average  Registrar level 
Side-effects  
Delayed transfusion reactions Average Registrar level 
Routine investigations Average All doctors 
What to do in a suspected transfusion 
reaction 
Easy All doctors 
Monitoring during transfusion Easy All doctors 
Massive transfusion reactions Average All doctors 
Clinical scenario Average  Registrar level 
 
The third section related to how the participant would like education to be conferred 
with regards to blood and blood products. 
 
2.5 Statistical analysis  
Completed questionnaires where collected. The responses were entered by the 
researcher into an excel spreadsheet for interpretation, based on study numbers to 
maintain anonymity of the participants. The researcher, supervisor and statistician 
viewed the data allowing them to appropriately analyse and interpret the responses, 
with the assistance of statistical software. 
 
Questions were allocated a mark of one to get a base mark for answered 
questionnaire. In order to get a mark for the difficulty grading, a mark of one was 
	 37	
given for easy questions, two for average questions and three for difficult questions. A 
mark of one was awarded for questions that all doctors should know, two for 
questions registrars should know and three for the questions that the specialists should 
know. An average score was thus obtained for comparison as a percentage. 
 
A student t test with two-tails was used to for statistical significance within the 
various groups that were compared. The two-tail method was used as participants 
could have a score higher or lower than the mean. The groups that were compared 
were the doctors of different levels of qualification. A comparison was also done 
between the different scoring systems. A p score < 0.05 was deemed to be statistically 
significant. 
 
2.6 Ethical considerations 
Written consent was obtained from the Heads of Departments of Internal Medicine as 
well as the Chief Executive Officers of the University of the Witwatersrand affiliated 
hospitals, i.e. Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani 
Baragwanath Academic Hospital and Helen Joseph Hospital, to carry out the study at 
their facilities (see Appendices D – F). 
 
Approval was also received from the University of Witwatersrand Post-Graduate 
Committee as well as the Human Research Ethics Committee (see Appendix G). 
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Doctors were then invited to participate in the study. A questionnaire together with a 
consent form was given. The consent form was required to be signed by willing 
participants prior to completing the questionnaire (see Appendix C). Questionnaires 
had study numbers and did not include the names of participants, in order to maintain 
anonymity. The researcher and supervisor had access to the questionnaires, while the 
statistician had access to the data. 
 
The study was conducted in accordance and with adherence to the principles of the 
Declaration of Helsinki 2008 (31) and South African Good Clinical Practice 
Guidelines (32). 
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CHAPTER 3: RESULTS 
 
3.1 Overview 
Of the approximately six hundred questionnaires distributed, two hundred 
questionnaires were completed within the six-month period giving a response rate of 
thirty-three percent. Forty-three percent of the questionnaires were from Charlotte 
Maxeke Johannesburg Academic Hospital (i.e. 85 questionnaires), thirty-one percent 
from Chris Hani Baragwanath Academic Hospital (i.e. 62 questionnaires) and twenty-
six percent from Helen Joseph Hospital (i.e. 53 questionnaires). There was a total of 
fourteen percent from consultants (i.e. 28 questionnaires), thirty-five percent from 
registrars (i.e. 70 questionnaires), nine percent from medical officers (i.e. 18 
questionnaires), ten percent from community service doctors (i.e. 20 questionnaires) 
and thirty-two percent from interns (i.e. 64 questionnaires) that participated in the 
study, having answered the study questionnaire. This is depicted in Table 3.1 below:  
 
Table 3.1 Breakdown of study participants  
Participants CMJAH CHBAH HJH  TOTAL 
Intern 21 23 20 64 
Community 
Service Doctor 12 4 4 20 
Medical Officer 4 9 5 18 
Registrar 32 21 17 70 
Consultant 16 5 7 28 
TOTAL 85 62 53 200 
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3.2 Results 
3.2.1 Red blood cell products 
 
Figure 3.1 Responses pertaining to Red Blood Cells 
 
The above figure depicts all the answers across the various groups of doctors for 
questions pertaining to red blood cells. More than fifty percent was achieved in five of 
the seven questions. Twenty-nine percent of respondents knew the correct price of a 
unit of blood. The majority that had incorrect answers had underestimated the correct 
price of the product. Fifty-five percent knew the correct storage duration of red blood 
cells with those getting it incorrect underestimating its viable period. Thirty-seven 
percent did not know when a blood warmer was required, while thirty-eight percent 
had the wrong indication for its use. Eighty percent knew the correct period over 
which blood needs to be transfused. Eighty-eight percent knew the expected 
haemoglobin increase with each unit of blood transfused, while ninety-seven percent 
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knew the correct threshold level at or below which patients require blood. Fifty-eight 
percent knew the true indication for leucodepleted blood. Of those that answered 
incorrectly, thirty-three percent gave an answer that related to a specific condition. 
Although it may be used in those specific conditions, the correct answer is a universal 
one incorporating the various conditions. 
 
3.2.2 Platelets 
 
Figure 3.2 Responses pertaining to Platelets  
 
More than fifty percent of the responders were able to answer half of the questions 
correctly. Thirty-six percent knew the correct price of platelets, with forty-five 
percent underestimating its value. The correct storage duration was known by thirty-
six percent, while sixty-four percent did not know the answer or provided the 
incorrect answer. This poses a great problem, as this is an expensive product that has 
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a short expiry date and needs to be used judiciously and appropriately. Sixty-three 
percent were aware that platelets should be stored and transported at room 
temperature, with the majority of the remainder being unsure. Two thirds were aware 
that platelets could be transfused in less than an hour and also knew the correct 
transfusion level for platelets. Transfusing platelets inappropriately poses an 
unnecessary risk to the patient without any significant benefit. The indication for the 
use of apheresis platelets was known by forty-four percent, with a further thirty 
percent assuming it only has a place in treating a haematological condition. 
 
3.2.3 Plasma products 
 
Figure 3.3 Responses pertaining to Plasma products 
 
Six of the seven questions were correctly answered by a third of the participants. The 
correct price of a unit of fresh frozen plasma was known by a third of the participants, 
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with forty-five percent underestimating its price. Fifty-four percent underestimated 
the period for which plasma is viable. Seventy-seven percent knew how long to 
transfuse the plasma over. Twenty-eight percent knew the correct dose for prescribing 
plasma in DIC, and thirty-two percent for TTP, which is related to the weight of 
patient. The majority of those that were incorrect approximated the dose for the 
weight of an average person. More than fifty percent of participants did not know the 
indication for the use of alternative plasma products. 
 
3.2.4 Consent 
 
Figure 3.4 Responses related to consent to blood product transfusion 
 
Correct responses were achieved by more than three quarters of the respondents for 
all seven of the questions. Inadequate consent was taken by twenty-three percent of 
participants, while twelve-and-a half percent were unaware that consent needs to be 
0%	10%	20%	
30%	40%	50%	
60%	70%	80%	
90%	100%	
Responses	related	to	consent	
incorrect	I	don’t	know	correct	
	 44	
taken for any blood or blood product administered. Thirteen percent of participants 
were unaware of the available blood and blood products, while the same proportion 
did not know what a blood alternative was. 
 
3.2.5 Blood ordering 
 
Figure 3.5 Responses related to Blood Ordering 
 
Fifty percent of the respondents answered five of the seven questions correctly. 
Twenty percent were unaware that only blood requires a compat tube, while thirty-
five percent overestimated the amount of time an order takes to be ready once 
initiated. This may be a more accurate measure in clinical practice, due to the high 
ordering rate. Fifty-seven to seventy percent of participants were unaware of how 
long a specimen would be kept before being discarded by blood bank. Platelet filters 
are different from a blood filter. Eighty-two percent were aware of this. Blood that is 
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not used should be returned to the blood bank. The returned blood cannot be used for 
another patient. However, another patient can use blood ordered in a BRB (blood on 
returnable basis) hamper, where the cold chain is not broken and the blood is returned 
within twelve hours. About half, i.e. forty-eight percent were unaware of this. 
 
3.2.6 Side effects 
 
Figure 3.6 Responses related to side effects of blood and blood products 
 
Fifty percent of participants correctly attained four of the six questions correct. Two 
thirds were unaware of what a potential delayed transfusion reaction would present 
like, while fifty percent were unaware of the effects of a massive blood transfusion. 
Ninety-five percent were able to follow the correct procedure should a transfusion 
reaction be suspected; while ninety-seven percent knew the correct observations to be 
monitored for a person on a blood transfusion, ensuring reactions are picked up 
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sooner. Knowing the infections that are screened by the blood bank helps identify a 
potential source, should a patient develop these bodily fluid spread infections namely: 
HIV, Hepatitis B, Hepatitis C and Syphilis. This was known by thirty-one percent of 
the participants. Eighty-four percent made the correct diagnosis in the reported 
clinical scenario question. 
 
3.2.7 Summary of sections 
 
Figure 3.7 Average scores achieved in the various sections 
 
More than fifty percent was achieved in four of the six sections with an average total 
of fifty-six percent for interns, fifty-eight percent for community service doctors, 
sixty-three percent for medical officers and registrars and sixty-four percent for 
consultants. This reveals that there is a stepwise increase in knowledge, but there is 
minimal difference from registrar level onwards. 
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A score greater than fifty percent is regarded as having satisfactory knowledge. All 
the groups achieved this satisfactory level with regards to red blood cells, consent, 
ordering of blood products and side effects of blood products. Knowledge with 
regards to platelets was between forty to fifty percent, while knowledge with regards 
to plasma ranged between twenty-five to thirty-five percent. Knowledge in these latter 
two sections is quite poor and requires much needed attention and intervention.  
 
 
Figure 3.8 Proportions of groups that achieved less than 50% correct answers 
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Figure 3.9 Proportions of groups that achieved more than 50% correct answers 
 
The most significant area where the participants achieved less than fifty percent is in 
regards to plasma products. Sixty-one percent of consultants, seventy percent of 
registrars, seventy-eight percent of medical officers, eighty-nine percent of interns 
and ninety-five percent of community services doctors all got less than fifty percent in 
this section. These are quite significant numbers and therefore this area needs special 
attention.  
Another area that needs attention is with regard to platelet transfusion. Fifty-five 
percent of the interns did not do well in this section, as well as forty-five percent of 
community service doctors, twenty-eight percent of medical officers, twenty-six 
percent of registrars and eighteen percent of consultants.  
Less than ten percent of participants got questions related to side effects and consent 
wrong.  
0%	10%	20%	
30%	40%	50%	
60%	70%	80%	
90%	100%	
Proportion	that	achieved	more	than	
50%	correct	answers		
intern	community	service	medical	ofCicer	registrar	consultant	
	 49	
Forty-six percent of consultants failed the ordering section. This is probably due to 
the fact that they do not usually order the blood products. Of concern is the thirty-one 
percent of interns that do not know this, as they are the ones that do most of the 
ordering of blood and blood products and the twenty-seven percent of registrars who 
in most circumstances give the instruction for the intern to carry out the order.  
 
3.2.8 How to impart information 
 
Figure 3.10 How information would like to be received 
 
A hundred percent of participants agreed that they would like further educational 
information with regards to blood and blood product usage. Thirty-five percent would 
like teaching in the form of pamphlets, twenty-seven percent would like seminars in 
this regard, and fourteen percent would like bedside teaching with two percent 
making other suggestions such as online portals and posters. A combination of these 
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different methods would be of benefit in improving the knowledge of blood and blood 
product usage amongst the medical doctors in the Department of Medicine at the 
Faculty of Health Sciences, University of the Witwatersrand affiliated academic 
hospitals. 
 
3.2.9 Comparing the different groups 
Statistical significance was looked for among the various groups to ascertain if there 
is a significant gap in knowledge. Below is a table showing the results using the 
double tail method. 
 
Table 3.2 P-values from different student t-tests among the various groups 
  p-value (two-tail) 
Intern vs. Community Service Doctor 0.4700 
Intern vs. Medical Officer 0.0139 
Intern vs. Registrar 0.0012 
Intern vs. Consultant 0.0039 
Community Service Doctor vs. Medical Officer 0.1683 
Community Service Doctor vs. Registrar 0.1502 
Community Service Doctor vs. Consultant 0.1014 
Medical Officer vs. Registrar 0.8321 
Medical Officer vs. Consultant 0.8026 
Registrar vs. Consultant 0.5936 
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The significant p-values are highlighted in the table above. Statistical significance is 
noticed from the level of interns compared to medical officers (p=0.0139), registrars 
(p=0.0012) and consultants (p=0.0039). 
 
3.2.10 Comparing the scoring of different scoring systems 
Comparing the results using the difficulty scale system revealed an average score of 
fifty-six percent by the participants, while the sample using the importance scale 
system yielded a fifty-four percent average score. This is much lower than the sixty-
one percent achieved with no scoring system. A statistically significant difference was 
found when comparing the base score (no scoring system) to importance 
(p=0.0000596) as well as difficulty (p=0.0000049). No statistically significant 
difference was shown between the importance and difficulty grading system. A 
similar stepwise increase in knowledge was seen in the various grading systems. 
 
Table 3.3 P-values from comparing the different scoring systems 
 
base vs. importance base vs. difficulty importance vs. difficulty 
p-value (two-tail) 0.0000596 0.0000049 0.4801303 
	 52	
 
Figure 3.11 Average score using difficulty score 	
 
Figure 3.12 Average scores using importance score 
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Figure 3.13 Average score with no scoring system 
 
The average for the questionnaire was sixty-one percent. The consultants achieved the 
highest score of sixty-four percent. The interns who averaged fifty-six percent 
achieved the lowest score. The medical officers and registrars both averaged sixty-
three percent. The community service doctors averaged fifty-eight percent. A similar 
gradient was seen across the different sections. 
  
There is an eight percent difference between interns and consultants. Medical officers 
have a similar score to the consultants, with a one percent difference. There is a 
statistical difference (p=0.0139) when comparing interns with medical officers. Mere 
progression from interns to medical officers or registrars is not enough to ensure 
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adequate knowledge of blood and blood products. An effort needs to be made in this 
regard to learn and study different aspects of blood transfusion. 
 
The best score was achieved in the section regarding consent with a score of eighty-
seven percent. The next best score was for the section regarding side effects, i.e. 
sixty-four percent. The section regarding red blood cell usage and blood product 
ordering averaged sixty percent. The lowest score was achieved in the section 
regarding plasma product usage, i.e. thirty percent. The section with regards to 
platelet transfusion usage also achieved a score of less than fifty percent, i.e. forty-
four percent. 
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CHAPTER 4: DISCUSSION 
 
4.1 Introduction  
Blood and blood product usage has changed over the centuries and have proven vital 
in the treatment plan of many patients. A package insert is not always available for 
these products, thus knowledge about these products are vital for the attending 
clinician in order to be able to use the products appropriately. Blood is not 
manufactured in a laboratory or factory, but rather gained from the generous, non-
remunerated donations of our citizens and should be used judiciously as availability 
can vary and is more often than not, limited. We thus set out to ascertain the level of 
knowledge present in doctors working in the Department of Medicine at the 
University of the Witwatersrand affiliated academic hospitals. 
 
4.2 Data interpretation 
A large number of questionnaires were circulated in order to achieve the desired two 
hundred questionnaires for the study. This number includes having given some 
doctors more than one questionnaire, as the first questionnaire was lost or misplaced 
and therefore not completed and returned.  It also includes participants rotating in and 
out of the various departments in Medicine, as part of their training. 
 
The number of questionnaires received from the different hospitals is not a true 
reflection of the size of the workforce at the various hospitals. Convenience sampling 
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was used in collection of the questionnaire. This may explain the discrepant collection 
rates. 
 
It was thought to be important to study the knowledge of a range of academic ranks, 
as all are involved in the ordering and administering of blood and blood products.  
Responses from a spectrum of doctors are also more likely to reveal deficiencies and 
strengths in this broad group of doctors.  Interns contributed to thirty-two percent of 
the cohort.  This population are still considered to be in training, however they are 
often the subset administering blood and blood products (in conjunction with medical 
officers and community service medical officers).  Thus, their understanding of blood 
transfusion and its complexities is vital.  However, the largest proportion of the group 
studied comprised of registrars in Medicine, i.e. thirty-five percent.  This population 
is most often the subset making the clinical decision to order the blood or blood 
products.  Registrars are also usually in the process of studying, thus they should be 
expected to have more detailed knowledge of blood transfusions.  Any deficits in this 
group could indicate a need for further training in the relevant sections that were 
assessed.  Consultants contributed to fourteen percent of the cohort. Consultants are 
often used as a measure of the knowledge of the people at the pinnacle at the 
profession.  
 
The three hospitals attached to the University of Witwatersrand were included as the 
sites from which the various doctors were selected. This provides for broader 
variability that such a study requires. Moreover, teaching methods at the different 
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facilities vary and registrars rotate through the different facilities during their training 
period. 
 
Responses to the different questions were analysed and are shown in the results 
section. This revealed that the gap in knowledge is statistically significant until 
doctors reach the level of a medical officer, after which the increase in knowledge is 
not statistically significant (p>0.05). This finding was consistent with a previous 
study done by Yudelowitz et al (28). This gradient is expected, as the further along a 
doctor progresses, so should their knowledge and experience.  
 
By grouping the questions together, we were able to get a better insight into what the 
baseline knowledge and areas of deficiency were in the participants. The use of 
platelets and plasma products requires most attention, not only as the lowest scores 
were achieved in this section but also the fact that scores of less than fifty percent 
were achieved. This was true for all levels of training, from interns to consultants. 
 
4.3 Comparison to South African data 
There is a paucity of studies in the South African setting, especially within the 
department of Medicine. Previous studies were conducted within the department of 
Anaesthesiology (28, 33). A comparison will be drawn between the study of 
Yudelowietz et al. and this study, as his study was also conducted at Chris Hani 
Baragwanath Academic Hospital (in the surgical and anaesthesiology departments) 
(28). However, the indications and amount of blood product use are not always 
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consistent in stable medical patients as compared to peri-operative patients that are 
dealt with by Anaesthesiologists. 
 
The questions in this study that were of a similar nature, to the Yudelowietz et al. 
study, is detailed and compared in table 9.1 below: 
 
Table 4.1 Comparisons of our study to Yudelowitz et al. study (28) 
Question  Yudelowitz et al. (28) 
(Percentage correct) 
Our study 
(Percentage correct) 
Red cell concentrate cost 29 29 
Haemoglobin transfusion level 72 97 
Haemoglobin increase 91 89 
Platelet cost 30 36 
Platelet transfusion temperature 52 63 
Platelet transfusion level 24 67 
FFP cost 27 34 
FFP dose 34 30 
Type of consent 31 83 
Cross match definition 55 82 
Type, screen and hold definition 48 42 
Blood hamper 38 34 
 
The results between the two groups are fairly similar in certain areas. The significant 
areas of discrepancy (difference of greater than ten percent) is noted in the 
haemoglobin and platelet transfusion levels, with a difference of twenty-five and 
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forty-three percent respectively, between the two groups. This is in keeping with a 
previous study showing variable use of platelet transfusion triggers (22, 34).  
The knowledge of the cost of the various blood products was comparable in the two 
groups, demonstrating that the knowledge regarding this aspect is was very poor. 
Only approximately a third of the participants knew the cost of these products.  
 
There is a global trend of increasing FFP use, with inappropriate indications for its 
use at times (34, 35). This is further compounded by not knowing the correct dose of 
FFP to be used (as evident in the correct response being noted in approximately one 
third of the participants in both studies).  
 
Doctors in Medicine faired best in the section with regards to knowledge of consent 
with an average score of eighty-seven percent for this section. This is surprisingly 
different to the lower figure of thirty-one percent in the other study (28). 
 
Blood can be ordered in different ways from the blood bank. This has significant 
implications on cost as well as availability of blood for transfusion (12, 19). Thirty-
four percent of the participants were aware that blood could be returned if ordered in a 
hamper to prevent wastage, should blood not be used. Forty-three percent were aware 
of the type, screen and hold (TSH) format of ordering blood. These results were 
consistent with the study by Yudelowitz et al. (28). 
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4.4 Comparison to International data 
Knowledge regarding blood and blood products or transfusion medicine is deficient 
worldwide, in both first and third world countries. This makes education in this regard 
of paramount importance to ensure safe and efficient practices globally (29).  
 
Many questionnaires have been formulated but very few validated. The questionnaire 
in this study has many questions similar to those validated by Haspel et al. in terms of 
addressing needs assessment. Thus the questions used in this study can be assumed to 
be of a good quality. Taking in to account that the exact questions were not asked, 
questions covering the same areas of concern are highlighted in table 4.1 below (30): 
 
Table 4.2 Comparison of questions to validated questionnaire by Haspel et al. (30) 
Question area in validated questionnaire, 
Haspel et al. (30) 
Corresponding question in our 
questionnaire 
Transfusion threshold 6 
Irradiated blood indication 7, 13 
Platelet transfusion threshold 12 
Platelet transfusion 8-13 
Acute transfusion reaction 35 (delayed transfusion reaction 
included) 
Managing a reaction 37, 38 
Plasma transfusion threshold 19, 20 
Reporting of reaction 37 
Infection risk 36 
Massive transfusions 39 
Correct identification 28, 29 
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TRALI 40 
Haemoglobin increase 5 
 
The opinion that almost all doctors worldwide feel that they require further teaching 
with regards to transfusion medicine is also an indication that this is an area of 
concern. Many different approaches have been adopted in different countries with 
varying results. In the United States studies it is felt that transfusion medicine requires 
sub-speciality training, while in Malaysia, Korea and Japan training should be 
included as part of the residency program. Training should however, be initiated at 
medical school level, as junior staff require knowledge in this field (29). 
 
The level of competency of junior doctors in the setting of this study was fifty-six per 
cent compared to sixty per cent when compared to that in the United Kingdom (36). 
Although the type of assessment used in the study by Graham et al. was different, 
there is great deficiency in the teaching that is provided at medical school in the field 
of transfusion medicine and this needs to be addressed in order to improve 
competency in transfusion medicine (37). Recent studies have shown a level of 
competency of forty-two per cent among doctors (post-internship) in Sri Lanka and 
forty-eight per cent among residents in India (38). This is much lower than the sixty-
one per cent in our study. Varying questionnaires make it difficult for direct 
comparison, but the general impression is that significant improvement in education is 
required in this field of medicine globally (39). 
 
	 62	
4.5 Summary 
The SANBS endeavours to ensure that their products are on par with international 
standards, regarding safety (2). Despite this, there are still risks involved with 
administering a transfusion. It is thus important to know what these risks are, and how 
to recognize and appropriately minimize and manage these risks. Ninety-five percent 
of the participants were aware of the procedure to follow when suspecting a 
transfusion reaction, while ninety-eight percent were aware of the correct monitoring 
of patients. However, more detailed knowledge of transfusion reactions was variable, 
ranging from thirty to eighty percent. This is in keeping with previous studies and is 
an area that should be targeted, when planning an education program (33).  
 
Experience in a field does bring about greater knowledge. This may not always be 
correct should adherence to current literature and guidelines not be followed. 
Although consultants faired better than the junior staff, on-going teaching and 
teaching from a junior level will help in improving the understanding and better use 
of blood and blood products (28). By setting the bench mark knowledge around blood 
and blood products at a higher level than it currently is, the knowledge base will 
improve and will be higher than that of the level of the current interns, and is likely to 
improve further in the upward career path of the doctor. Only forty-three percent of 
doctors reported training at medical school about blood and blood products. Thus, 
there is a clear need for education commencing at the undergraduate level. 
 
Various hospitals have adopted a local blood committee at their facility in order to 
audit the use of blood and blood products (use / wastage / costs / returns etc.). This 
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has been used to great effect in improving the correct utilization of this scarce 
resource (40). The committee is also instrumental in providing appropriate education 
and haemovigilance (reviewing untoward reactions etc.). 
 
An annual blood transfusion seminar is held at Chris Hani Baragwanath Academic 
Hospital where the trends of usage of blood and blood products at the facility are 
highlighted. Basic aspects of transfusion including safety, indications, costs, side 
effects and monitoring are discussed. In addition, ‘state of the art’ advances and 
alternatives to the use of blood and blood products are highlighted at these seminars. 
 
Various modalities of teaching (such as seminars, lectures, provision of booklets and 
pamphlets, practical training etc.) are required to maintain and improve current 
knowledge and practices. All this is an attempt to optimize the appropriate and 
judicious use of this valuable, but scarce and expensive resource (27).  Advances in 
technology can be used for this purpose as well, with promising results as shown with 
virtual patient cases (41, 42). 
 
4.6 Limitations 
Limitations of the study can be found within the convenience sampling method that 
was used. Equal numbers of the various sub groups were not obtained, which may 
contribute to bias. Doctors were also based at different University of the 
Witwatersrand affiliated hospitals. The undergraduate studies of the different doctors 
vary as they may have been undertaken at various Universities across the country 
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where the teaching varies from institution to institution. Doctors up to registrar level 
usually rotate through the different departments and may even rotate through the 
various hospitals, which in some way removes some of the bias mentioned above. As 
junior doctors often obey the instruction of their ‘seniors’, their knowledge base may 
be influenced by the knowledge of their seniors. 
 
Another limitation is the fact that as a multiple-choice format was used for the 
questionnaire, respondents may have chosen one of the given options rather than an 
answer based on their inherent knowledge. This could also lead to bias. 
 
4.7 Recommendations 
Implementation and impact of any intervention would need to be assessed. Awareness 
around blood and blood products among doctors will also help improve knowledge in 
this field. Research into the cause of lack of knowledge among doctors may also be of 
value. 
 
4.8 Conclusion 
On-going teaching around blood and blood product usage is required at the University 
of the Witwatersrand affiliated hospital at all levels, from interns through to 
consultants to ensure efficacious use of this scarce, but most valuable resource. 
Certain areas require more attention than others, i.e. platelet and plasma product 
usage, but a refresher on all sections will be of benefit. Various methods can be 
employed, but a combination of different methods is likely to be more beneficial. 
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APPENDIX B: QUESTIONNAIRE  
  
A
1
a intern b community service doctor c medical officer d
registrar         
year               
1  2  3  4
e consultant
2
a CMJAH b CHBAH c HJH
B
1
a R 750 - 00 -R 1 000 - 00 b
R 1 000 - 00 - 
R 1 250 - 00 c
R 1 250 - 00 - 
R 1 700 - 00 d
R 1 750 - 00 - 
R 2 000 - 00 e I don't know
2
a 1 day b 1 week c 1 -2  month d 1 year e I don't know
3
a cold agglutinin disease b
massive blood 
transfusion c
neonatal 
exchange 
transfusion
d routine transfusions e I don't know
4
a 1-2 hours b 2-6 hours c 6-8 hours d >8 hours e I don't know
5
a 0.5 g/dl b 1.5 g/dl c 2 g/dl d 3 g/dl e I don't know
6
a <8 g/dl b <10 g/dl c <12 g/dl d <14 g/dl e I don't know
7
a no other blood available b
patients 
needing 
repeated 
transfusions
c
only for 
haematology 
patients
d only in renal patients e I don't know
Assessment of the knowledge of usage of blood and blood products amongst medical 
doctors in the Department of Medicine at the Faculty of Health Sciences, University of 
Witwatersrand affiliated academic hospitals 
Questionnaire of the study
What is your current designation?
In which of the following circumstances will you not use a blood warmer?
What is the approximate storage duration after preparation, before blood will expire?
What is the approximate cost of a unit of (adult) packed red cell concentrate?
In each of the following questions, please circle the answer/option you think is correct
Demographics
Study Questionnaire
The following questions pertain to red blood cells
By how much will the haemoglobin increase with each unit of blood?
When will you use leucodepleted red cell concentrate?
At what haemoglobin level will you routinely consider transfusing an uncomplicated patient?
Over what duration of time does each unit of blood need to be transfused in an 
uncomplicated patient who is not actively bleeding?
study number
Which hospital are you currently working at?
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8
a R 1 500 - 00 - R 2 500 - 00 b
R 2 500 - 00 - 
R 5 000 - 00 c
R 6 500 - 00 - 
R 9 000 - 00 d
> R10 000 - 
00 e I don't know
9
a <1 day b 3-5 days c 10 days d 1 month e I don't know
10
a 1-6°C b room temperature c
body 
temperature d
in a blood 
warmer e I don't know
11
a < 1 hour b 1-2 hours c 2-4 hours d 4-6 hours e I don't know
12
a <10 x 109/l b <50 x 109/l c <70 x 109/l d <100 x 109/l e I don’t know
13
a
when no 
platelets are 
available
b
for all 
bleeding 
patients
c
needing 
repeated 
platelet 
transfusions
d only in haematology e I don’t know
14
a R 200 - 00 b R 400 - 00 c R 750 - 00 d R 1 200 - 00 e I don't know
15
a 1 day b 1 week c 1 month d 1 year e I don't know
16
a <6 hour b 6-12 hours c 12-24 hours d 48 hours e I don't know
17
a 15ml/kg b 30-40ml/kg c 2 units d 4 units e 8 units
18
a 15ml/kg b 30-40ml/kg c 2 units d 4 units e 8 units
19
a
alternate with 
normal FFP in 
DIC
b TTP c
DIC with 
hypofibrinoge
naemia
d haemophillia B e I don't know
20
a
alternate with 
normal FFP in 
DIC
b TTP c
DIC with 
hypofibrinoge
naemia
d haemophillia A e I don't know
What is the shelf life of FFP?
When will you use single donar apheresis platelet concentrates?
At what platelet count will you routinely consider transfusing platelet concentrates?
What is the approximate storage duration (on a platelet adgitator) before the platelet 
concentrate will expire?
What is the approximate cost of a unit of (adult) platelet concentrate?
The following questions pertain to platelets
At what temperature do platelet concentrates need to be transported and transfused? 
The following questions pertain to plasma products?
What is the cost of a unit of fresh frozen plasma (FFP)?
Over what duration of time does each unit of platelets need to be transfused?
Disseminated Intravascular Coagulopathy (DIC)?
Thrombotic Thrombocytopaenic Purpura (TTP)?
Cryo-poor fresh frozen plasma?
Cryoprecipitate?
When will you consider the use of the following plasma products:
At what dose will you use plasma in the following situations:
Once FFP is thawed, it should be transfused within what period of time?
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21
a blood b platelets c plasma d none e all blood products
22
a informed & verbal b
verbal & 
written c
informed & 
written d
informed 
verbal & 
written
e none
23
a patient b super- intendant c
parent / 
guardian d doctor e I don't know
24
a nurse b intern c consultant d prescribing doctor e I don't know
25
a why products administered b
benefits of 
receiving c
harms of 
receiving d
agreement to 
take product e
all of the 
above
26
a sedate and give the blood b
get consent 
from the 
super- 
intendant
c
respect the 
patients 
wishes and 
don’t give 
anything
d
respect 
patient wishes 
and offer an 
alternative 
option, if 
available
e I don't know
27
a Erythro - poeitin b Haemopure c
recombinant 
factor 7 d
fresh frozen 
plasma e I don't know
28
a blood b platelets c plasma d all products e I don't know
29
a 30 min b 1 - 2 hour c 4 - 6 hours d 1 day e I don't know
30
a <1 hour b 2 - 4 hours c 4 - 6 hours d 1 day e I don't know
31
a 24 hours b 48 hours c 72 hours d 96 hours e I don't know
32
a 24 hours b 48 hours c 72 hours d 96 hours e I don't know
33
a yes b no c I don't know
34
a
within 1 hour 
if in a brown 
paper bag
b
within 12 
hours in a 
brown paper 
bag
c
within 1 hour 
in a 
temperature 
controlled 
hamper
d
within 12 
hours in a 
temperature 
controlled 
hamper
e I don't know
How long will blood be secured for a patient if it is ordered on a Type, Screen and Hold (TSH) 
format?
How long will blood be secured for a patient once ordered on a standard format?
If an adult patient needs blood and blood products electively, but does not consent, what do 
you do?
The following questions are related to ordering of blood products
Which product generally requires a compat together with the request form?
How long will you need to wait for blood ordered in a standard cross-match format?
How long will you need to wait for platelets/FFP if available at blood bank?
Which one of the following options are not acceptable to Jehova's Witness patients?
What information should be discussed with the patient before administering a transfusion?
The following questions are related to consent around blood products?
Ideally, which products require patient consent for administration?
Ideally, what type of consent should be taken?
Who cannot  give consent?
Ideally, who should be taking informed consent from the patient?
Is a platelet administration set required for transfusion of platelets?
When can blood be returned to blood bank?
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35
a intravascular haemolysis b
post 
transfusion 
purpura
c fluid overload d anaphylaxis e I don't know
36
a HIV, Hep B, Syphillis b
HIV, Hep B, 
Hep C, 
Syphillis
c HIV, Hep B, Hep C d
HIV, Hep B, 
Hep C, CMV e
HIV, Hep b, 
Hep C, CMV, 
Syphillis
37
i
ii
iii
iv
v
vi
vii
a i, ii, iii, iv b i, v c i, vi d vii, i e I don't know
38
a temperature b
blood 
pressure and 
pulse
c general condition d
respiratory 
rate e
all of the 
above
39
a hyper calcaemia b fluid overload c
hyper 
kalaemia d
thrombo 
cytopaenia e I don't know
40
a
transfusion 
related acute 
lung injury 
(TRALI)
b pulmonary oedema c
pulmonary 
thrombo-
embolic 
disease
d broncho-pneumonia e
febrile non-
haemolytic 
transfusion 
reaction
C
1
a never b medical school c
during 
internship d
within the past 
2 years
2
a yes b no
a seminars b formal lectures c
pamphlets / 
booklets d
bedside 
teaching e other
remove the line and return it together with the blood to blood bank
draw blood specimens and a urine sample and send it to blood bank, together with a 
completed transfusion reaction form
monitor the patient closely and treat and problems appropriately
wait for the transfusion to complete before doing anything
give steroids and continue transfusion
wait 30 min and restart the tranfusion
A 40 year old male presents with acute respiratory distress two hours after receiving blood 
from his multiparous younger sister. Clinically he is tachypnoeic, pyrexial, hypotensive and 
cyanosed. His JVP is not raised. His chest x-ray shows bilateral pulmonary infiltrates. What is 
the most likely diagnosis?
When have you last had teaching about blood and blood product usage?
General
What do you need to do if you suspect a transfusion reaction?
What routine monitoring is needed when administrating blood?
stop the transfusion immediately
Please choose the correct set of options
Would you like teaching about blood and blood products and its usage?
If YES, how would you like this teaching to be conducted?
if option e chosen, please specify
any further comments you would like to add
The following questions pertain to side-effects of blood products
Which of the following is regarded as a delayed reaction to blood product usage?
Which infections are routinely tested for by the blood bank?
Please return the completed questionnaire to one of the following sites:
A) A collection box at the medicine secrataries' offices at the respective hospitals
B) Post completed forms to P O Box 909, Randfontein, 1760
Which of the following is not regarded as a complication of a massive blood transfusion?
	 78	
APPENDIX C: INFORMATION AND CONSENT FORM 
 
Study Details 
Study Number:  
Study Doctor:  Muhammad Laher 
Site Address:  Helen Joseph Hospital, Chris Hani Baragwanath Academic Hospital 
and Charlotte Maxeke Johannesburg Academic Hospital 
Contact Details:  
Cell:  084 581 2418 
Email:  laherm@msn.com 
 
Participant Information Sheet 
My name is Muhammad Laher.  I am currently a medical registrar in the Department 
of Medicine at the Faculty of Health Science; University of Witwatersrand affiliated 
academic hospitals. 
I would like to invite you to participate in a research study, to try and ascertain the 
knowledge that medical doctors have with regard to various aspects of blood 
transfusion.  Before agreeing to participate in this study, it is important for you to read 
and understand the explanation of the study.  If you have any questions, please do not 
hesitate to ask me.   
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The study has been submitted to the University of Witwatersrand Human Research 
Ethics Committee (HREC) and written approval has been granted.  The study number 
is M140622. 
Your participation in the study is voluntary.  If you decide to participate, you are free 
to withdraw from the study at any time.  If you choose to participate, you will be 
asked to sign a consent form.  Your refusal to participate, or your early withdrawal, 
will not affect you in any way.  
What is the purpose of this study? 
This study is intended to assess the knowledge about blood and blood products and its 
usage, costs, side effects, administration, available alternatives and ethical 
considerations.  Gaps in knowledge of the participants will hopefully be identified and 
possible areas of redress in regard to teaching/education will be made in an attempt to 
solve the problems areas identified. 
How will this affect me?  
You will be asked to complete a questionnaire designed to cover knowledge about 
various aspects of blood transfusion. The questionnaire should take approximately 20 
– 30 minutes of your time.  The data obtained in this questionnaire will be kept 
strictly confidential. You will be allocated a study number thus keeping your personal 
details anonymous. The study number will be the only identifier used to analyse the 
results of the study.   
There are no known risks to you if you participate in the study.   
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By participating, you will help in allowing me to assess the knowledge base of 
medical practitioners related to blood and blood products and identify whether there 
are gaps or possible areas of deficiency, which can then be subsequently addressed.   
Informed Consent Form 
By signing this form, I confirm that 
1. I have read the information provided above and the study has been explained 
to me.  
2. I have been given enough time to make my decision and an opportunity to ask 
questions.  All of my questions have been answered to my satisfaction. 
3. I agree to participate in this study voluntarily. 
4. I understand my right to refuse or withdraw from the study at any stage. 
 
________________________________________  
Name of participant 
 
_______________________________________ ______________  
Signature of participant                                             Date 
 
_______________________________________  
Witness 
 
_______________________________________ ______________  
Signature of witness                         
Date 
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APPENDIX D: PERMISSION LETTER FROM CHRIS HANI 
BARAGWANATH ACADEMIC HOSPITAL 
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APPENDIX E: PERMISSION LETTER FROM HELEN JOSEPH HOSPITAL 
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APPENDIX F: PERMISSION LETTER FROM CHARLOTTE MAXEKE 
JOHANNESBURG ACADEMIC HOSPITAL 
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APPENDIX G: ETHICS APPROVAL LETTER 
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APPENDIX H: POSTGRADUATE COMMITTEE APPROVAL LETTER 
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APPENDIX I: TURN-IT-IN LETTER 
  
